Research Topics
Species | Stephen HowellSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropinIsao Kanatani
Department of Medicine and the Rebecca and John Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093 0819, USA
Cancer Chemother Pharmacol 68:979-90. 2011..To selectively kill LHR-expressing tumors, granzyme B (GrB) was linked to a protein in which both chains of human chorionic gonadotropin were yoked together (YCG)...- Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs AbraxaneZhongling Feng
Biogroup, Nitto Denko Technical Corporation, 501 Via Del Monte, Oceanside, CA 92058, USA
Cancer Chemother Pharmacol 65:923-30. 2010..7-fold relative to that produced by PTX formulated in Cremophor. In this study, the efficacy of PGG-PTX was compared to that of Abraxane, an established nanoparticular formulation of PTX, in three different tumor models... - Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenograftsXinghe Wang
Biogroup, Nitto Denko Technical Corporation, 501 Via Del Monte, Oceanside, CA 92058, USA
Cancer Chemother Pharmacol 65:515-26. 2010..The purpose of this study was to compare the pharmacokinetics and tissue distribution of PTX following injection of either free PTX or PGG-PTX in mice... - Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potencyXiaoqin Yuan
Department of Medicine and Rebecca and John Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0819, USA
BMC Cancer 11:61. 2011..perfringens enterotoxin (CPE), which binds to claudins 3 and 4, to deliver a toxin in the form of recombinant gelonin (rGel) to the cytoplasm of the human ovarian carcinoma cell line 2008... 
Resistance to apoptosis in prostate cancer cellsS B Howell
Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California 92093, USA
Mol Urol 4:225-9;discussion 231. 2000..One such example is a recently identified small organic compound that can inhibit p53 function and thus protect normal tissues against radiation-induced apoptosis without impairing killing of p53-deficient tumor cells...
Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancerS B Howell
Moores UCSD Cancer Center, University of California, San Diego, California 92093, USA
Int J Gynecol Cancer 18:20-5. 2008..New information about how cisplatin and carboplatin are transported into ovarian carcinoma cells points to novel strategies for further improving the therapeutic effectiveness of intraperitoneal chemotherapy...- Copper transporters and the cellular pharmacology of the platinum-containing cancer drugsStephen B Howell
Department of Medicine, Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA
Mol Pharmacol 77:887-94. 2010.... - Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cellsGoli Samimi
Department of Medicine, University of California San Diego, La Jolla, California, 92093-0058, USA
Clin Cancer Res 10:4661-9. 2004.... - Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cellsKuniyuki Katano
Department of Medicine, Chemistry and the Cancer Center, University of California, San Diego, La Jolla, California, USA
Clin Cancer Res 10:4578-88. 2004..These results provide evidence that DDP directly interacts with ATP7B to trigger its relocalization and that ATP7B mediates resistance to DDP by sequestering it into vesicles of the secretory pathway for export from the cell... - Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7BGoli Samimi
Department of Medicine, the Rebecca and John Moores University of California San Diego Cancer Center, Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, USA
Mol Pharmacol 66:25-32. 2004..However, in this model system, although copper is readily exported after vesicular sequestration, the platinum drugs are not... - Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copperKuniyuki Katano
Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California 92093-0058, USA
Cancer Res 62:6559-65. 2002..These results are consistent with the concept that DDP enters and exits from the cell via transporters that normally mediate copper homeostasis... - The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatinChristopher A Larson
Rebecca and John Moores Cancer Center and Department of Medicine, University of California, San Diego, La Jolla, California, USA
Mol Pharmacol 78:333-9. 2010.... - Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transportersGoli Samimi
Department of Medicine, The Rebecca and John Moores UCSD Cancer Center, Mail code 0819, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
Cancer Chemother Pharmacol 57:781-8. 2006..These results suggest that JM118 will retain activity in cells in which DDP resistance is due to the loss of CTR1, but not in cells in which resistance is due to enhanced expression of ATP7A or ATP7B... - Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and CarboplatinBrian G Blair
Moores Cancer Center and Department of Medicine, University of California, San Diego, La Jolla, California
Clin Cancer Res 15:4312-21. 2009..We sought to determine the effect of CTR2 on influx, intracellular trafficking, and efflux of cisplatin and carboplatin... - The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cellsAlison K Holzer
Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla 92093-0058, USA
Mol Pharmacol 66:817-23. 2004.... - Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cellsAlison K Holzer
Department of Medicine and the Rebecca and John Moores Cancer Center, University of California at San Diego, La Jolla, California 92093-0058, USA
Clin Cancer Res 10:6744-9. 2004..The effect was observed at DDP concentrations within the range found in the plasma of patients being treated with DDP, and it occurred very quickly relative to the half-life of the drug... - Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patientsGoli Samimi
Department of Medicine and the Cancer Center, University of California-San Diego, La Jolla, California 92093-0058, USA
Clin Cancer Res 9:5853-9. 2003..These findings are in agreement with results of in vitro studies from this laboratory demonstrating that increased expression of ATP7A renders cells resistant to cisplatin and carboplatin... - The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cellsKuniyuki Katano
Department of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0058, USA
Mol Pharmacol 64:466-73. 2003..We conclude that expression of ATP7B regulates sensitivity to CBDCA as well as to DDP and copper and that a transporter that normally mediates copper homeostasis modulates the cellular pharmacology of CBDCA... - Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatinAlison K Holzer
Department of Medicine and the Rebecca and John Moores UCSD Cancer Center, 3855 Health Sciences Drive, Room 3344, La Jolla, CA 92093-0819, USA
Mol Pharmacol 70:1390-4. 2006..We conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clinical spectrum of activity... - Cross-resistance to cisplatin in cells with acquired resistance to copperRoohangiz Safaei
Department of Medicine 0058, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0058, USA
Cancer Chemother Pharmacol 53:239-46. 2004..The results are consistent with the idea that transporters and chaperones that normally mediate Cu homeostasis also directly or indirectly modulate the accumulation of DDP... - Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cellsBrian G Blair
Moores Cancer Center, Department of Medicine, University of California, La Jolla, CA 92093 0819, USA
Mol Pharmacol 77:912-21. 2010..Therefore, these two copper transporters have opposite effects on DDP sensitivity. CTR2 expression is regulated by copper availability via the copper-dependent regulator ATOX1... - Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1Danielle D Jandial
Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, California, USA
Clin Cancer Res 15:553-60. 2009..We sought to determine whether proteasome inhibition using bortezomib would prevent human CTR1 (hCTR1) degradation and increase platinum accumulation in ovarian cancer cells... - The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiaeXinjian Lin
Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California 92093, USA
Mol Pharmacol 62:1154-9. 2002..These results indicate that CTR1 function markedly influences the uptake of all of the clinically used platinum-containing drugs and suggest that this copper transporter may also transport DDP... - Effects of the loss of Atox1 on the cellular pharmacology of cisplatinRoohangiz Safaei
Moores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0819, United States
J Inorg Biochem 103:333-41. 2009..Ctr1 was found to be polyubiquitinated in an Atox1-dependent manner during CDDP exposure. In conclusion, Atox1 is required for the polyubiquitination of Ctr1 and the Ctr1-mediated uptake of CDDP... - The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugsChristopher A Larson
Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA
Mol Pharmacol 75:324-30. 2009..We conclude that CTR1 mediates the initial influx of DDP, CBDCA, and L-OHP and is a major determinant of responsiveness to DDP both in vitro and in vivo... - Transport of cisplatin by the copper efflux transporter ATP7BRoohangiz Safaei
Department of Medicine, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0819, USA
Mol Pharmacol 73:461-8. 2008..Copper and DDP each inhibited the ATP-dependent transport of the other. These results establish that DDP is a substrate for ATP7B but is transported at a much slower rate than copper... - The internalization and degradation of human copper transporter 1 following cisplatin exposureAlison K Holzer
Department of Medicine and the Rebecca and John Moores Cancer Center, University of California at San Diego, La Jolla, California, USA
Cancer Res 66:10944-52. 2006..Because hCTR1 is a major determinant of early DDP uptake, prevention of its degradation offers a potential approach to enhancing tumor sensitivity... - cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistanceGoli Samimi
Department of Medicine and the Cancer Center, University of California, 9500 Gilman Drive, La Jolla, San Diego, 92093-0058, CA, USA
Cancer Chemother Pharmacol 55:1-11. 2005.... - The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatinChristopher A Larson
Moores Cancer Center and Department of Medicine, University of California, San Diego, La Jolla, 92093, United States
Biochem Pharmacol 80:448-54. 2010..We conclude that cDDP interacts with hCTR1 both at (40)MXXM(45) and at sites outside the N-terminal domain that produce the conformational changes that trigger degradation... - Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatinGoli Samimi
Department of Medicine and Rebecca and John Moores UCSD Cancer Center, 0819, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0819, USA
Cancer Chemother Pharmacol 59:301-12. 2007..The goal of this study was to identify molecular determinants of sensitivity and resistance to JM118, the active metabolite of satraplatin, an orally bioavailable cisplatin analog that has activity in prostate cancer... - Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cellsRoohangiz Safaei
Department of Medicine, and the Rebecca and John Moores Cancer Center, University of California San Diego, San Diego, CA 92093, USA
Clin Cancer Res 11:756-67. 2005..We sought to identify the subcellular compartments in which cisplatin [cis-diamminedichloroplatinum (DDP)] accumulates in human ovarian carcinoma cells and define its export pathways... - The role of copper transporters in the development of resistance to Pt drugsRoohangiz Safaei
Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, 9500 Gilman Drive, San Diego, La Jolla, CA 92093 0058, USA
J Inorg Biochem 98:1607-13. 2004..Negative associations between the expression of ATP7A and ATP7B and the outcome of Pt therapy further support the significance of the Cu homeostasis proteins as both markers of and contributors to Pt resistance... - Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cellsRoohangiz Safaei
Rebecca and John Moore University of California at San Diego Cancer Center, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
Mol Cancer Ther 4:1595-604. 2005.... - Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugsRoohangiz Safaei
Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093 0058, USA
Crit Rev Oncol Hematol 53:13-23. 2005..Appreciation of the role of the Cu transporters in the development of resistance to DDP, CBDCA, and L-OHP offers novel insights into strategies for preventing or reversing resistance to this very important family of anticancer drugs... - DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistanceXinjian Lin
Department of Medicine 0058, University of California, San Diego, La Jolla, CA 92093, USA
Mol Cancer Ther 5:1239-47. 2006..The DNA damage response activated by cisplatin is accompanied by a p53- and MMR-dependent increase in homologous recombination even between adduct-free sequences... - Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cellsTimothy C Cheng
Department of Medicine, The University of California Medical Center, La Jolla, San Diego, 92093-0819, USA
Cancer Chemother Pharmacol 58:384-95. 2006..The genes discovered by this extensively replicated analysis are candidates for prediction of DDP responsiveness in ovarian cancer patients... - DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repairXinjian Lin
Department of Medicine and the Cancer Center, University of California-San Diego, La Jolla, CA 92093, USA
Clin Cancer Res 12:563-8. 2006.... - Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer modelDanielle D Jandial
Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0819, USA
Gynecol Oncol 115:362-6. 2009..We compared the uptake of IP administered DDP and CBDCA into human ovarian carcinoma nodules of various sizes growing on the peritoneal surface of nu/nu mice... - DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistanceFang Wu
Department of Medicine and the Cancer Center, University of California San Diego, La Jolla, California 92093, USA
Cancer Res 64:8029-35. 2004..We conclude that when cisplatin adducts are present in the DNA, polymerase zeta is an important contributor to cisplatin-induced genomic instability and the subsequent emergence of resistance to this chemotherapeutic agent... - Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptorsXiaoqin Yuan
Department of Medicine and the Rebecca and John Moores University of California San Diego Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
Mol Cancer Ther 8:1906-15. 2009..We conclude that CPE(290-319) effectively targeted TNF to ovarian cancer cells and is an attractive targeting moiety for development of CPE-based toxins for therapy of ovarian carcinomas that overexpress CLDN3 and CLDN4... - CD44-targeted microparticles for delivery of cisplatin to peritoneal metastasesShyh Dar Li
Moores Cancer Center, University of California, San Diego, La Jolla, California 92093 0819, USA
Mol Pharm 7:280-90. 2010..Hyplat was more effective than cisplatin at slowing the growth of intraperitoneally inoculated A2780 ovarian cancer cells and improving survival thus demonstrating the potential of Hyplat to enhance the efficacy of ip chemotherapy... - Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanineMaida M de las Alas
Cancer Center, University of California, San Diego, La Jolla, California, USA
Mol Pharmacol 62:1198-206. 2002..The results suggest that this region is important to the ability of the mismatch repair system to mediate drug sensitivity and to maintain genomic stability... - Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug deliverySeong Deok Kong
Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093 0358, USA
Bioconjug Chem 18:293-6. 2007.... - Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cellsXinjian Lin
Department of Medicine and the Moores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0819, USA
Mol Pharmacol 69:1748-54. 2006..We conclude that hREV1-dependent processes are important determinants of DDP-induced genomic instability and the development of resistance... - Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivoBrian G Blair
Moores Cancer Center and Department of Medicine, University of California, San Diego, La Jolla, California, USA
Mol Pharmacol 79:157-66. 2011..CTR2 regulates the transport of cDDP in part through control of the rate of macropinocytosis via activation of Rac1 and cdc42. Selective knockdown of CTR2 in tumors offers a strategy for enhancing the efficacy of cDDP... - Expression of the human copper influx transporter 1 in normal and malignant human tissuesAlison K Holzer
Department of Medicine and Pathology and the Rebecca and John Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USA, and Department of Surgery, Umea University Hospital, Sweden
J Histochem Cytochem 54:1041-9. 2006..No hCTR1 expression was found in several common types of cancer, suggesting that hCTR1 expression is not commonly enhanced by transformation... - NMR and mutagenesis of human copper transporter 1 (hCtr1) show that Cys-189 is required for correct folding and dimerizationSangwon Lee
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA
Biochim Biophys Acta 1768:3127-34. 2007.... - Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!David S Alberts
J Clin Oncol 20:3944-6. 2002 - Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatinTsuyoshi Okuda
Department of Medicine 0058, University of California-San Diego, La Jolla, CA
Mol Pharmacol 67:1852-60. 2005..Most importantly, hREV1 controls the rate of emergence of resistance to DDP at the population level. Thus, hREV1 is an important contributor to DDP-induced genomic instability and the subsequent emergence of resistance... - Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulinZobeida Cruz-Monserrate
Building 469, Room 104, National Cancer Institute at Frederick, Frederick, MD 21702, USA
Mol Pharmacol 63:1273-80. 2003..If the latter is correct, diazonamide A and its oxygen analog should have uniquely potent inhibitory effects on the dynamic properties of microtubules... - A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumorsJeany M Rademaker-Lakhai
The Netherlands Cancer Institute, Amsterdam, The Netherlands
Clin Cancer Res 10:3386-95. 2004..However, it remains to be determined whether AP5280 can actually increase Pt delivery to the DNA of tumor cells in man as has been shown in experimental models... - Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiaeDavid Kowalski
Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Mol Pharmacol 74:1092-100. 2008..Taken together, our results indicate that dysregulation of the purine nucleotide biosynthesis pathways and the addition of exogenous purines can modulate cisplatin cytotoxicity in Saccharomyces cerevisiae... - Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancersSharon P Wilczynski
Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA
Hum Pathol 36:242-9. 2005..This study demonstrates that PDGFR alpha, PDGFR beta, and c-kit are expressed in a high percentage of epithelial ovarian cancers suggesting that tyrosine kinase inhibitors may be useful in the treatment of these tumors... - Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patientsMario Campone
Centre Rene Gauducheau, Nantes, France
Cancer Chemother Pharmacol 60:523-33. 2007..To determine the maximum tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compound, in advanced solid tumor patients... - Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery systemJohn R Rice
Access Pharmaceuticals, Inc, Dallas, Texas, USA
Clin Cancer Res 12:2248-54. 2006..CONCLUSIONS: AP5346 has a substantially better therapeutic index than oxaliplatin. AP5346 produced a marked increase in the delivery of diaminocyclohexane Pt to the tumor and tumor DNA over and above that attainable with oxaliplatin...
Research Grants
- UCSD Cancer Center Training Program in Drug DevelopmentStephen Howell; Fiscal Year: 2007..Special efforts will be made through our partnership grant and other vehicles to recruit and retain exceptional minority and women candidates to the program. ..
- Cisplatin resistance mediated by cooper export pathwaysStephen Howell; Fiscal Year: 2009..These studies will also further elucidate the mechanisms that mediate resistance to this important class of chemotherapeutic agents and suggest clinically relevant strategies for reversing resistance. ..
- Cisplatin resistance mediated by cooper export pathwaysStephen Howell; Fiscal Year: 2009..These studies will also further elucidate the mechanisms that mediate resistance to this important class of chemotherapeutic agents and suggest clinically relevant strategies for reversing resistance. ..
- Cisplatin Resistance mediated by copper export pathwaysStephen B Howell; Fiscal Year: 2010....
- CISPLATIN RESISTANCE DUE TO LOSS OF DNA MISMATCH REPAIRStephen Howell; Fiscal Year: 2005..Thus, it is very likely that the mechanisms underlying the DDP-induced mutagenicity will be of fundamental importance to understanding the genomic instability produced by many types of cellular injury. ..
- The Center for Cancer Drug Development (C2D2)Stephen Howell; Fiscal Year: 2004..abstract_text> ..
- CISPLATIN RESISTANCE DUE TO LOSS OF DNA MISMATCH REPAIRStephen Howell; Fiscal Year: 2001..of MMR increase the spontaneous rate of mutation to resistance to other clinically important chemotherapeutic agents?; and 4) does loss of MMR increase the ability of cisplatin to mutagenize tumor cells to other chemotherapeutic agents? ..
- Cisplatin Resistance mediated by copper export pathwaysStephen Howell; Fiscal Year: 2004..The results of these studies are expected to be of fundamental importance in identifying novel strategies for overcoming intrinsic resistance and reversing acquired resistance to this very important chemotherapeutic agent. ..
- Control of the cellular pharmacology of the platinum-containing drugs by CTR1Stephen B Howell; Fiscal Year: 2010....